AVACTA GROUP PLC — Director's Dealing 2018

Mar 13, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5787H

Avacta Group PLC

13 March 2018

13 March 2018

Avacta Group plc

("Avacta" or "the Group" or "the Company")

Director/PDMR Shareholding

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, announces that its Chief Executive Officer, Dr Alastair Smith has today purchased 35,800 ordinary shares of 10p each ("Ordinary Shares") at a price of 41.92p per Ordinary Share.

Following this transaction, Dr Smith's total beneficial interest in the Group is 606,309 Ordinary Shares, representing approximately 0.9% of Avacta's issued share capital. In addition, Alastair Smith has a joint interest in 1,640,000 shares in the share capital of the Company; such shares are jointly held by certain Directors individually and Avacta Group Trustee Limited in its capacity as trustee of The Avacta Employees' Share Trust.

Enquiries:

Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer	Tel:  +44 (0) 844 414 0452 www.avacta.com
finnCap Ltd Geoff Nash / Giles Rolls - Nominated Adviser Tim Redfern / Alice Lane / Nikita Jain - Corporate Broking WG Partners David Wilson Nigel Barnes Claes Spang	Tel:  +44 (0) 207 220 0500 www.finncap.com Tel:  +44 (0) 203 705 9318 Tel:  +44 (0) 203 705 9217 www.wgpartners.co.uk
Yellow Jersey PR (Financial Media and IR) Sarah Hollins	Tel: +44 (0)7764 947137 avacta@yellowjerseypr.com

Notes to Editors

Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $100bn despite their shortcomings.  Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability.  Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes.  Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

To register for news alerts by email go to www.avacta.com/investor-news-email-alerts

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.                            

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Alastair Smith

2.                            

Reason for the Notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/Amendment

Initial notification

3.    

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Avacta Group Plc

b)

LEI

2138009U3EG31OPMGH36

4.    

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary shares of 10p

Identification code

GB00BYYW9G87

b)

Nature of the transaction

Purchase of ordinary shares

c)

Price(s) and volume(s)

Price(s)	Volume(s)
41.92 pence	35,800

d)

Aggregated information:

·      Aggregated volume

·      Price

See above

e)

Date of the transaction

13 March 2018

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHFKNDKBBKDKND